The Alliance for Clinical Trials in Oncology opened a randomized Phase III study testing an intensified regimen for patients with grade‑3 IDH‑mutant astrocytoma, the group announced. Supported by the National Cancer Institute, the trial will compare standard therapy with an experimental consolidation strategy to determine whether outcomes and progression can be improved in this aggressive glioma subtype. IDH mutation status guides both prognosis and therapeutic hypotheses; the trial will collect molecular correlates to link response to tumor biology.